Compare AbCellera Biologics Inc (ABCL) vs OneSpan Inc (OSPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs OneSpan Inc — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while OneSpan Inc trades at $14.67 (market cap $559.43M). The key difference: AbCellera Biologics Inc is far larger — about 4.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.45% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OSPN | |
|---|---|---|
Market Cap | $2.35B | $559.43M |
Sector | Health | Technology |
52-Week High | $8.12 | $18.05 |
52-Week Low | $2.78 | $10.15 |
Enterprise Value | $1.99B | $517.63M |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
OneSpan (OSPN) trades at $15.09, up 4.5% today, showing strong momentum despite trading above the analyst consensus price target of $13.50. The stock exhibits bullish technical signals with recent earnings beats and robust profitability metrics including 28.5% net income margin and 27.8% ROE. Recent corporate developments include leadership team expansion and digital credentials launch, signaling growth initiatives.
The outlook remains positive with strong analyst support (67% buy ratings) and attractive valuation multiples (P/E 8.3x), though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains earnings momentum, while execution risks and market volatility present headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
